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Tau proteinA pathological hallmark of many neurodegenerative diseases is the aggregation of proteins. Protein aggregate
formation may be linked to a failure of the ubiquitin proteasome system (UPS) and/or the autophagy path-
way. The UPS involves the ubiquitination of proteins followed by proteasomal degradation. Deubiquitination
of target proteins is performed by proteases called deubiquitinating proteins (DUBs). Inhibition of DUBs may
lead to the dysregulation of homeostasis and have pathological consequences. To assess the effects of DUB-
inhibition, we have used the oligodendroglial cell line, OLN-t40, stably expressing the longest human tau iso-
form. Cells were incubated with PR-619, a broad-range, reversible inhibitor of ubiquitin isopeptidases. Incu-
bation with PR-619 led to morphological changes, the upregulation of heat shock proteins (HSP), including
HSP70 and αB-crystallin, and to protein aggregates near the MTOC, containing ubiquitin, HSPs, and the ubi-
quitin binding protein p62, which may provide a link between the UPS and autophagy. Thus, inhibition of
DUB activity caused stress responses and the formation of protein aggregates resembling pathological inclu-
sions observed in aggregopathies. Furthermore, PR-619 led to the stabilization of the microtubule network,
possibly through the modulation of tau phosphorylation, and small tau deposits assembled near the MTOC.
Hence, organization and integrity of the cytoskeleton were affected, which is particularly important for the
maintenance of the cellular architecture and intracellular transport processes, and essential for the function-
ality and survival of neural cells. Our data demonstrate that DUB inhibitors provide a useful tool to elucidate
the manifold mechanisms of DUB functions in cells and their dysregulation in neurodegenerative diseases.
This article is part of a Special Issue entitled: Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Pathological ﬁlamentous protein inclusions are characteristically
observed in various neurodegenerative diseases [1,2]. These contain
speciﬁc disease-associated proteins, such as the microtubule associat-
ed protein tau or α-synuclein, and colocalize with a variety of other
proteins, which are not necessarily components of the ﬁbrillary de-
posits butmay bind to them, e.g. heat shock proteins, cytoskeletal pro-
teins, and components of the ubiquitin proteasome system (UPS) [3].
α-Synuclein is the major constituent of Lewy bodies in Parkinson's
disease (PD) and of glial cell inclusion bodies in multiple system atro-
phy (MSA), an adult onset neurodegenerative disease with symptomsbiquitin Drug Discovery and
olecular Neurobiology, Univer-
any. Tel.: +49 441/798 3422;
ldenburg.de
rights reserved.of parkinsonism. Pathological inclusions of tau are prominent in Alz-
heimer's disease (AD) in neurons. In progressive supranuclear palsy
and corticobasal degeneration they occur in nerve cells and glia, and
speciﬁcally originate in oligodendrocytes, the myelin forming cells of
the central nervous system [1,2]. Aberrant proteins are formed when
cells are subjected to stressful conditions, e.g. oxidative stress, heat
stress or stress induced by proteasomal impairment [3]. To eliminate
misfolded proteins, heat shock proteins (HSPs), acting as molecular
chaperones, have the capacity to refold damaged proteins and target
irreversibly damaged proteins to the UPS for ubiquitination and thus
have the potential to protect against neurodegeneration [3–6].
The covalent posttranslational modiﬁcation of cellular proteins by
ubiquitin, a highly conserved 76-amino acid residue polypeptide, oc-
curs in a multistep enzymatic modiﬁcation requiring three different
enzymes, namely E1 (ubiquitin activating enzyme), E2 (ubiquitin
conjugating enzyme) and E3 (ubiquitin ligase). Substrates can be
conjugated to a single ubiquitin molecule or a polyubiquitin chain.
K48-linked poly Ub-chains generally target proteins for proteasomal
degradation, while K63-linked protein chains are involved in a variety
of cellular processes, including autophagy, cell sorting and DNA repair
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autophagy, and several proteins function as a linker between both
systems, including the ubiquitin binding protein p62/sequestosome-
1 [8–10].
Cellular ubiquitin exists in the form of free monomers and in a
pool conjugated to proteins. Elevated levels of ubiquitin conjugates
are observed after various stress conditions and inclusion bodies are
often associated with ubiquitinated proteins [2,6]. Also, the synthesis
of ubiquitin may be increased after stress. Ubiquitin is a relatively
long-lived protein in vivo and efﬁciently removed from its conjugates
by deubiquitinating enzymes (DUBs). DUBs represent a large group of
enzymes opposing the function of E3 ligases. They maintain ubiquitin
homeostasis and prevent ubiquitin degradation together with the
substrates of the 26S proteasome by removing ubiquitin chains before
the substrate enters the central proteolytic chamber of the protea-
some [7,11,12]. Hence, a complex system is required to balance the
attachment and removal of ubiquitin from protein substrates.
The importance of the ubiquitin dependent pathways in the ner-
vous system has become increasingly clear in recent years [6,7]. Pro-
teasomal inhibition has been demonstrated to promote the formation
of intracellular inclusion bodies [4,13,14], and a loss of proteasomal
function may contribute to aging and neurodegeneration [15]. We
have shown before that oligodendrocytes are speciﬁcally sensitive
to proteasomal inhibition, causing the formation of tau-positive ag-
gregates containing the small HSP αB-crystallin and ubiquitin
[4,14,16]. However, little is known about the effects of DUB-
inhibition on cell viability and protein aggregate formation in nerve
cells or glia.
The present study was undertaken to elucidate the effects of DUB-
inhibition on protein aggregate formation in OLN-t40 cells, a stably
transfected oligodendroglial cell line expressing the longest human
isoform of tau [17,18]. Cells were treated with PR-619, a cell-
permeable, broad-range, reversible inhibitor of deubiquitylases and
ubiquitin-like isopeptidases [19,20]. The data show that incubation
with PR-619 led to morphological changes, the upregulation of HSPs
and accumulation of ubiquitinated protein species. Protein aggregates
assembled in aggresome-like structures near the microtubule orga-
nizing center (MTOC). These were positively stained by antibodies
against ubiquitin, αB-crystallin, HSP70, and p62. Furthermore, incu-
bation with PR-619 affected the microtubule network and led to the
accumulation of small punctuated tau deposits around the MTOC
which were surrounded by but did not colocalize with ubiquitin im-
munoreactivity. Thus, inhibition of DUB activity caused a change in
cell morphology and the formation of protein inclusions as observed
in pathological situations. These data underline the importance of
DUBs as possible targets for therapeutic intervention in neurodegen-
erative diseases.
2. Materials and methods
2.1. Materials and antibodies
Cell culture media were from Gibco/BRL (Grand Island, NY, USA).
PR-619 was purchased from LifeSensors (Philadelphia, PA, USA). MG-
132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) and proteolytic sub-
strate II (Z-Leu-Leu-Glu-AMC)were purchased fromMerck (Darmstadt,
Germany). MTT (1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan)
was from USB Corporation (Cleveland, OH, USA). Taxol and alkaline
phosphatase were purchased from Sigma (St. Louis, MO, USA).
For Western blot analysis the following antibodies were used, the
working dilutions are given in brackets. Anti-ubiquitin mouse mono-
clonal antibody (mAb) VU-1 (1:1000) was from LifeSensors (Phila-
delphia, PA, USA). Rabbit polyclonal anti-p62 antibody (1:1000),
mAb anti-αB-crystallin (1:1000), and mAb anti-α-tubulin (1:1000)
were from Sigma (Munich, Germany), polyclonal antibody (pAb)
anti-HSP32/HO-1 (1:1000), and mAb anti-HSP70 (1:1000) werefrom StressGen (Ann Arbor, MI, USA). Tau 17026 (1:1000), a
phosphorylation-independent rabbit pAb made against the largest
human recombinant tau isoform; mAb tau-1 (1:1000), speciﬁc for
nonphosphorylated epitope located in amino acid residues
189–209; mAb paired helical ﬁlament-1 (PHF-1; 1:1000), speciﬁc
for phosphorylated serine 396/404 were from Dr. Virginia Lee (Phila-
delphia, PA, USA). MAb 12E8 (1:500), speciﬁc for phosphorylated ser-
ine 262 was from Dr. Seubert (Elan Pharmaceuticals, South San
Francisco, CA, USA). HRP-conjugated anti-mouse IgG and anti-rabbit
IgG were from Jackson ImmunoResearch (West Grove, PA, USA).
2.2. Cell culture
OLN-93 cells stably transfected with the longest human tau iso-
form were used in this study [4,17]. Cells were kept in DMEM supple-
mented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
Glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin.
2.3. Immunoblot analysis
Cellular monolayers of control and treated cells were washed with
PBS once, scraped off in sample buffer containing 1% SDS and boiled
for 10 min. Protein contents in the samples were determined accord-
ing to Neuhoff et al. [21]. For immunoblotting, total cellular extracts
(5–20 μg protein per lane) were separated by one-dimensional SDS-
PAGE using 7.5–12.5% polyacrylamide gels and transferred to nitro-
cellulose membranes (Whatman, Dassel, Germany; 0.2 μm) or PVDF
membranes (BioRad, Hercules, CA, USA) for detection of ubiquitin
with anti ubiquitin antibody VU-1. The blots were saturated with
TBS (20 mM Tris, 136.8 mM NaCl, pH 7.5) containing 5% dry milk
and incubated with the individual antibodies overnight at 4 °C. For in-
cubation with anti-ubiquitin antibody VU-1, blots (PVDFmembranes)
were washed in PBS and incubated with 0.5% glutaraldehyde in PBS
for 20 min. After washing with PBS the blots were saturated with
TBS containing 5% dry milk and incubated with the VU-1 antibody
overnight. After washing with TBS-T (TBS with 0.1% v/v Tween 20),
incubation with HRP-conjugated anti-mouse (1:10,000) or anti-
rabbit IgG (1:10,000) was carried out for 1 h at RT. After washing
with TBS-T, blots were visualized by the enhanced chemilumines-
cence (ECL) procedure as described by the manufacturer (Thermo
Scientiﬁc, Rockford, IL, USA). All experiments were carried out at
least 3 times with similar results.
2.4. Indirect immunoﬂuorescence
Cells were cultured on poly-L-lysine-coated glass coverslips for
48 h in DMEM/10% FCS and then subjected to PR-619 and MG-132
as indicated. After washing with PBS, cells were ﬁxed and perme-
abilized with ice-cold methanol for 7 min. Cells were washed three
times and incubated overnight at 4 °C with the following antibodies,
the working dilutions are given in brackets: mouse mAb anti-αB-
crystallin (1:200), mouse mAB anti-ubiquitin (FK2; Enzo Life Sci-
ences, Lörrach, Germany; 1:400), mouse mAb anti-α-tubulin
(1:200), rabbit pAb anti-α-tubulin (Sigma Aldrich, St. Louis, MO,
USA; 1:100), mouse mAb anti-HSP70 (1:200), rabbit mAb anti-p62
(1:1000), rabbit pAb anti-tau (tau 17024), mouse mAb tau (tau-1).
After washing with PBS, cells were incubated for 1 h with Texas
Red-conjugated (1:100) and FITC-conjugated (1:100) secondary anti-
bodies (Jackson ImmunoResearch, West Grove, PA, USA), washed
with PBS and mounted. Nuclei were stained by 4′, 6-diamidino-2-
phenylindole (DAPI) (1.5 μg/ml) included in the mounting medium
(Vectashield; Vector Laboratories, Burlingame, CA, USA). Fluorescent
labeling was studied using a Zeiss epiﬂuorescence microscope (Ober-
kochen, Germany) equipped with a digital camera using a plan-
neoﬂuar objective (100×) or a Leica TCS SL confocal laser scanning
microscope (Wetzlar, Germany).
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To assess the cytotoxic potential of PR-619, MTT-assay was carried
out. Brieﬂy the OLN-t40 cells were plated on PLL-coated 96-microwell
cell culture plates and grown as indicated above. Ten microliters of
MTT solution (5 mg/ml in PBS) was added to the wells containing
100 μl medium and plates were incubated for 4 h. Thereafter, 100 μl
of a solubilization solution (10% sodium dodecyl sulfate in 0.01 mol/l
HCl) was added and incubated overnight to dissolve the formazan
salt. Quantiﬁcation was then carried out with a microplate reader
(Biorad, Munich, Germany) at 595 nm, using a 655 nm ﬁlter as a
reference. Data are expressed as percentage of the untreated controls,
and values represent the means±SD of sixteen microwells each of
two independent experiments (n=32).Fig. 1. Cytotoxicity and effects on proteasomal activity. (A) Effect of PR-619 on cell mor-
phology. OLN-t40 cells were incubated with 8–10 μM PR-619 for 24 h, as indicated. Co,
untreated control. Hoffman modulation contrast images are shown. Scale bar, 100 μm.
(B) Determination of cytotoxic potential. Cells were exposed to different concentrations
of PR-619 as indicated. After 24 h of incubation aMTT assaywas performed. Co, untreated
control. Values represent the means±SD of 16 microwells each of two independent ex-
periments (n=32). (C) Proteasomal activity was determined in cell lysates treated
with 40 μM PR-619 for 30 min at 37 °C (lysate) and in cell lysates prepared from PR-
619 (9 μM, 24 h) treated live cells (cells). Cytoplasmic lysates were incubated with the
proteasomal inhibitor MG-132 (10 μM, 30 min) and cells were treated with 3 μM MG-
132 as positive controls. The post-glutamyl-peptidase-hydrolase activity was determined
using ﬂuorogenic substrate Z-Leu-Leu-Glu-AMC. Data are expressed as percent of the
untreated control and show the mean±SD from 3 independent experiments.2.6. Proteasome activity assays
Proteasome activity was determined using ﬂuorescence assays.
Post-glutamyl-peptidase-hydrolase activity of the proteasome was
assayed by ﬂuorometric measurement of the release of 7-amido-4-
methylcoumarin from the synthetic substrate Z-Leu-Leu-Glu-AMC
(proteasome substrate II, S2). Proteasome activity was determined
in cell lysates treated with PR-619 or MG-132, and also in cell extracts
derived from live cells treated with PR-619 or MG-132.
For measurement of proteasome activity in cell lysates, OLN-t40
cells were kept as described, harvested in ice-cold proteolysis assay
buffer (10 mM Tris/HCl (pH 7.2), 0.035% SDS, 5 mM MgCl2, 5 mM
ATP) and sonicated. For each sample, protein concentration was de-
termined according to Neuhoff et al. [21]. Aliquots of 350 μl each,
with a protein concentration of 1 μg/μl, were incubated with 40 μM
PR-619 or 10 μM MG-132. Thereafter 1 μl of proteasome substrate II
per 100 μl lysate was added and contents were incubated for 30 min
at 37 °C. Finally the hydrolysis of the substrate was measured by a
ﬂuorometer at 380 nm excitation wavelength and 440 nm emission
wavelength.
Proteasome activity in cell lysates prepared after treatment of live
cells with PR-619 and MG-132 was determined as described by Keller
et al. [22]. Brieﬂy, OLN-t40 cells were incubated with PR-619 (9 μM,
24 h) and MG-132 (1 μM), harvested in ice cold proteolysis assay
buffer, and sonicated. Protein concentrations of the resulting lysates
were determined according to Neuhoff et al. [21]. Aliquots of 350 μl
each, with a protein concentration of 1 μg/μl, were incubated with
50 μM of proteasome substrate II at 37 °C. Fluorescence was deter-
mined after 30 min at 380 nm excitation and 440 nm emission in a
ﬂuorescent microplate reader (FluoroCount, Packard). Proteasomal
activity was determined as an increase in ﬂuorescence of the reaction
products. Each experiment was repeated 3 times involving 5 samples
per group.
2.7. Microtubule binding assay
To determine the association of proteins with the microtubules
(MTs) of intact cells after PR-619 treatment, a MT binding assay was
performed as described [18]. Brieﬂy, cells were harvested in high
salt RAB buffer (0.1 M Tris, 0.5 mMMgSO4, 1 mM EGTA, 2 mM dithio-
threitol, and 0.75 M NaCl, pH 6.8) supplemented with 0.1% Triton X-
100, 20 μM Taxol, 2 mM GTP, and a mixture of protease inhibitors
(Complete Mini; Roche Diagnostics, Mannheim, Germany) and
2 mM PMSF at 37 °C. Cell lysates were homogenized with 15 strokes
in a warm Dounce homogenizer, then immediately centrifuged for
20 min at 100,000×g at 37 °C. The supernatant containing soluble tu-
bulin was removed and the protein concentration determined. The
remaining pellet was resuspended in a 1:2 volume of sample buffer
corresponding to the total volume of supernatant after normalizing
to total protein. The samples were subjected to immunoblot analysisas above. The ratio of proteins bound to MTs (P, pellet) versus un-
bound (SN, supernatant) was assessed by comparing the immunore-
activities in these two fractions.
Fig. 2. PR-619 leads to the induction of heat shock proteins and to an increase of ubiquitinated proteins. (A) Concentration dependent effects. Cells were either left untreated (Co) or
were exposed to different concentrations of PR-619 as indicated, or to MG-132 (3 μM; MG) for 24 h. Cell lysates were prepared and subjected to immunoblot analysis using anti-
bodies against HSP70, HSP32, αB-crystallin, ubiquitin (VU-1), p62, and α-tubulin, as indicated on the right. Treatment of cells with PR-619 effectively causes the accumulation of
HSPs, including HSP70, HSP32 and αB-crystallin and leads to an increase of p62 and ubiquitinated proteins. (B) Time dependent effects. Cells were treated with PR-619 (9 μM) for
3–24 h, as indicated, or with MG-132 (3 μM) for 24 h, and cell lysates were analyzed by immunoblot procedure using the same antibodies as in (A), indicated on the right.
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Isolation of soluble and insoluble proteins from OLN-t40 cells was
performed as described by Dou et al. [23]. Brieﬂy, cells were lysed in a
lysis buffer (0.5% Triton-X-100, 1 mM EDTA, 50 mM Tris HCl, pH 8.0,
120 mMNaCl) supplemented with protease inhibitors mixture (Com-
plete Mini; Roche Diagnostics, Mannheim, Germany) and centrifuged
at 15,000×g into supernatant (SN) and pellet (P) fractions. The
resulting fractions were supplemented with sample buffer and the
pellets taken up in sample buffer for immunoblot procedure as de-
scribed earlier. Equal amounts of control, PR-619 and MG-132 treated
samples were loaded.
2.9. Dephosphorylation of cell extracts
For dephosphorylation, cells were harvested in PBS, centrifuged,
resuspended in dephosphorylation buffer (5 mM Tris pH 7.9, 10 mN
NaCl, 1 mM MgCl2, 0.1 mM DTT) supplemented with protease inhibi-
tors mixture (Complete Mini; Roche Diagnostics, Mannheim, Germa-
ny) and sonicated. Lysates, with a protein concentration of 1 μg/μl,
were either incubated with alkaline phosphatase (25U/100 μg pro-
tein) for 1 h at 37 °C or remained untreated. Thereafter lysates were
supplemented with sample buffer for immunoblot procedure as de-
scribed earlier.
3. Results
3.1. Accumulation of ubiquitinated proteins and inhibition of proteasome
activity in live cells after treatment with PR-619
To assess the cytotoxic potential of PR-619, OLN-t40 cells were in-
cubated for 24 h with various concentrations. Cell viability was deter-
mined by MTT assay and revealed that PR-619 exerted concentration-
dependent cytotoxicity in a very narrow concentration range of
7–10 μM. Half maximal cytotoxicity was observed after a 24 h treat-
ment with 9–10 μM, which also caused the cells to retract theirprocesses and appear morphologically damaged (Fig. 1A, B). For the
following experiments a concentration of 9 μM was chosen and cells
were incubated for 24 h. Higher concentrations and longer periods
of incubation were not advisable, since severe cytotoxic effects
occurred.
PR-619 according to the manufacturer's protocol (LifeSensors Inc.)
[19] does not inhibit the enzymatic activity of the proteasome. To ver-
ify this and to test whether the accumulation of ubiquitinated pro-
teins per se (see below and Fig. 2) leads to an overload of the UPS,
thereby inhibiting its functions, proteasomal activity was determined
in cell lysates and living cells using a ﬂuorescence assay as described
earlier [24]. The effects of PR-619 were compared to the effects of
MG-132, belonging to a class of peptide proteasome inhibitors,
which effectively inhibits proteasome activity in OLN-t40 cells [18].
Fig. 1C demonstrates that PR-619 (up to 40 μM) added directly to a
cell lysate for 30 min did not exert a signiﬁcant inhibitory effect on
proteasomal activity, while MG-132 (10 μM) completely abolished
proteasomal activity in cell lysates within 30 min. In contrast thereto,
when live cells were incubated with PR-619 (9 μM, 24 h) proteasomal
activity was reduced to 50% (Fig. 1C). After treatment with MG-132
(3 μM, 24 h) proteasomal activity was impaired and remained at a
40% level. Hence, PR-619, unlike MG-132, did not inhibit the enzy-
matic activity of the proteasome in cellular lysates but only when
taken up by living cells.
To assess the accumulation of ubiquitinated protein species, cells
were incubated with PR-619 in a time- and concentration-
dependent manner. Cell lysates were prepared and analyzed by im-
munoblot procedure. Similar to the effect of MG-132, PR-619 caused
an increase in the abundance of ubiquitinated proteins within 24 h,
which was observed at the concentration range used (7–12.5 μM)
(Fig. 2). Additionally cell lysates were analyzed for p62 and the pres-
ence of HSPs, namely HSP70, HSP32 which is an indicator of oxidative
stress, and αB-crystallin, a small HSP which often is a constituent of
glial cell inclusion bodies. Fig. 2 depicts that PR-619 caused the upre-
gulation of all analyzed HSPs within 24 h. Furthermore, an increase in
p62 abundance was observed which was maximal after 7 h of
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inhibition of DUBs by PR-619 in OLN-t40 cells causes a stress response
and the recruitment of p62, which is also observed when cells are
treated with proteasome inhibitors.
3.2. PR-619 causes the formation of protein aggregates
Next we addressed the question, whether DUB inhibition and the
accumulation of ubiquitinated protein species is connected to protein
aggregate formation. Indirect immunoﬂuorescence staining was car-
ried out using antibodies against ubiquitin and tubulin, to analyze
the microtubule (MT) network. Ubiquitin-positive protein aggregates
were observed as small punctuated dots after 3–7 h of treatment with
PR-619 (9 µM). These increased with time and appeared as larger de-
posits surrounding the nuclei after 18–24 h (Fig. 3). At the same timeFig. 3. Time-dependent formation of ubiquitin containing protein aggregates after treatment
(D–F), 7 h (G–), 18 h (J–) or 24 h (M–O), and indirect immunoﬂuorescence staining was
antibody) (B, E, H, K, N; green). Overlay with DAPI (C, F, I, L, O; blue). Arrowhead points tothe MT-network was disturbed and MTs appeared more bundled and
the microtubule organizing center (MTOC) was very distinct (Fig. 3M,
arrow).
To further characterize the protein deposits double immunoﬂuo-
rescence was performed using antibodies against tubulin and αB-
crystallin, ubiquitin (FK2), HSP70 or p62. As demonstrated in Fig. 4
after treatment with PR-619 (9 μM, 24 h) loosely packed punctuated
protein aggregates were observed and also more compact
aggresome-like deposits around the MTOC next to the cell nucleus
were prominent. These aggregates positively stained for αB-
crystallin, ubiquitin, HSP70 and p62 (Fig. 4A). To further assess
whether these proteins were colocalized within the deposits, confocal
microscopy was carried out using double immunoﬂuorescent stain-
ing. This conﬁrmed that immunoreactivities of all three proteins
were found in colocalization with p62 (Fig. 4B).with PR-619. Cells were either left untreated (A–C) or treated with 9 μM PR-619 for 3 h
performed with antibodies against α-tubulin (A, D, G, J, M; red) and ubiquitin (FK2
the MTOC. Scale bar, 20 μm.
Fig. 4. HSPs and p62 are recruited to the aggregates and colocalize with ubiquitin after treatment with PR-619. (A) OLN-t40 cells were either left untreated (Co; a, d, g, j) or incu-
bated with 9 μM PR-619 for 24 h, as indicated on the top, and indirect immunoﬂuorescence was carried out with antibodies against α-tubulin (red) and antibodies against αB-
crystallin, ubiquitin (FK2), HSP70 and p62 (green) as indicated on the right panel. Shown are the merged images with nuclear DAPI staining (blue). Scale bar: 20 μm. Note that
protein accumulations appear as loosely packed aggregates (b, e, h, k) or as more compact aggresome-like structures (c, f, i, l). (B) Confocal images demonstrate that p62 and
HSPs are colocalized in the accumulations. Cells were treated with 9 μM PR-619 for 24 h and indirect immunoﬂuorescence was performed with antibodies against p62 (red) and
ubiquitin (FK2), HSP70, or αB-crystallin (green) as indicated. Confocal images of merged images (one section; 0.2 μm) are shown. Scale bar: 20 μm.
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As mentioned above, PR-619 treatment caused the alteration of
the MT network, MTs appeared stabilized and more bundled
(Fig. 3). To investigate whether this effect resembles a treatment
with Taxol, representing a MT stabilizing drug, cells were incubatedwith PR-619 (9 μM, 24 h) or Taxol (0.1 μM, 7 h) and indirect immuno-
ﬂuorescence was carried out using antibodies against p62, to demon-
strate protein aggregate formation, and α-tubulin. Fig. 5A shows that
both PR-619 and Taxol caused the stabilization of the MT network.
This effect was not observed after treatment with MG-132 (Fig. 5A).
While Taxol acts through binding to the MTs and inhibiting their
Fig. 5. PR-619 affects the organization of the microtubule network in OLN-t40 cells. (A) Cells were either untreated (Co; a–c) or treated with 9 μM PR-619 (24 h; d–f), 0.1 μM Taxol
(7 h; g–i) or with 3 μM MG-132 (24 h; j–l). After the incubation cells were analyzed by indirect immunoﬂuorescence staining with antibodies against p62 (a, d, g, j; red) and
α-tubulin (b, e, h, k; green). Overlay with DAPI staining (c, f, i, l; blue). Scale bar: 20 μm. After treatment with PR-619 and Taxol, microtubules appear stabilized and the MTOC
is more pronounced as compared to untreated control and MG-132 treated cells. (B) PR-619 does not affect the microtubule network of OLN-93 cells lacking tau. Cells were either
untreated (a–c) or treated with PR-619 (9 μM, 24 h; d–f), and indirect immunoﬂuorescence double staining was performed with antibodies against p62 (a, d; red) andα-tubulin (b,
e; green) in OLN-93 cells. a–c, untreated control; d–f PR-619 (9 μM) treated cells. Scale bar: 20 μm.
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Fig. 6. Treatment of cells with PR-619 leads to the formation of small tau aggregates around the MTOC not colocalizing with ubiquitin. (A) OLN-t40 cells were either left untreated
(a–c) or treated with 9 μM PR-619 (d–f) for 24 h and indirect immunoﬂuorescence was carried out with antibodies against polyclonal anti-tau 17024 (a, d; green) and α-tubulin
(b, e; red). Overlay with DAPI staining (c, f; blue). Scale bar: 20 μm. (B) Confocal microscopy of tau aggregates. Cells were treated with 9 μM PR-619 for 24 h and indirect immu-
noﬂuorescence staining was carried out using anti-tau (17024; green) and anti-ubiquitin (FK2; red) antibodies. (c) Merged images. Scale bar: 20 μm. Note that the punctuated
tau accumulations are not colocalized with ubiquitin aggregates.
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t40 cells expressing tau may be linked to its inﬂuence and posttrans-
lational modiﬁcation of tau. Using OLN-93 cells, not expressing tau,
indirect immunoﬂuorescence studies using antibodies against p62
and tubulin revealed that PR-619 although leading to protein aggre-
gate formation, has no pronounced MT stabilizing effect (Fig. 5B).
This prompted us to investigate whether PR-619 induced protein
aggregates also contained the microtubule associated protein (MAP)
tau and to analyze tau phosphorylation. Fig. 6 indicates that tau-
positive aggregates are formed after the treatment with PR-619
(9 μM, 24 h). These are often prominent around the MTOC (Fig. 6A),
however they do not directly colocalize with ubiquitin immunoreac-
tivity as demonstrated by confocal microscopy (Fig. 6B). Furthermore,
after immunoprecipitating cell lysates with tau antibodies, we could
not detect ubiquitinated tau species in PR-619 treated cells (data
not shown).
To test whether PR-619 has an inﬂuence on tau phosphorylation,
we treated OLN-t40 cells with PR-619 (7–10 μM, 24 h) and subjected
cell lysates to immunoblot procedure, using antibodies against total
tau (tau 17024), dephosphorylated tau (tau-1) and tau hyperpho-
sphorylated at Ser262 (12E8) or at Ser396/404 (PHF-1). The data show
that PR-619 caused the dephosphorylation of tau, as indicated by an
increase in tau-1 immunoreactivity, and a decrease in PHF-1 immuno-
reactivity (Fig. 7A). However, an increase in 12E8 immunoreactivity
was observed, indicating that PR-619 caused a hyperphosphorylation
at this epitope. Dephosphorylated tau migrates with a lower apparent
molecular weight in SDS polyacrylamide gel (Fig. 7A). To further testto what extent tau-dephosphorylation is involved in the present sys-
tem, cell extractswere dephosphorylated by alkaline phosphatase, be-
fore separation by SDS page and immunoblot procedure. Fig. 7B
depicts that after dephosphorylation, tau migrated at a lower molecu-
lar weight andwas not recognized by the 12E8 antibody. Furthermore,
tau-1 immunoreactive bands after treatment with PR-619 only partly
shifted to the position of tau dephosphorylated by alkaline phospha-
tase, which corroborates that tau is not completely dephosphorylated
by PR-619. Indirect immunoﬂuorescence further shows that after
treatment with PR-619 dephosphorylated tau (tau-1) is found in con-
junction with total tau bound to MTs in the cytoplasm and also is pre-
sent in the small aggregates around the MTOC (Fig. 7C).
3.4. PR-619 promotes the association of tau, ubiquitin and p62 with
microtubules and alters their solubility
Inhibition of DUBs by PR-619 may on the one hand lead to an in-
creased binding property of tau to the MTs and on the other hand
cause the recruitment of ubiquitin and p62 to MTs. p62 binds to poly-
ubiquitin chains via its ubiquitin binding domain (UBA) and is neces-
sary for the formation of aggresome-like structures which are
assembled from smaller aggregates via retrograde transport along
the MTs [9,26]. Hence we isolated MTs from control and treated
cells after stabilization with Taxol. Immunoblot procedure was car-
ried out with the soluble fraction (SN) and the pellet fraction (P),
representing the MT-associated fraction using antibodies against α-
tubulin, tau, p62 and ubiquitin. As demonstrated in Fig. 8A, the
Fig. 7. Inhibition of DUBs leads to a dephosphorylation of tau. (A) OLN-t40 cells were treated with PR-619 (7–10 μM) for 24 h. Co, untreated control. Cell lysates were analyzed by
immunoblot procedure with phosphorylation-independent polyclonal anti-tau 17024 antibody, reacting with total tau, and a panel of phosphorylation-dependent antibodies (tau-
1, 12E8, PHF-1) as indicated on the right. (B) Lysates of control (Co) and treated (9 μM PR-619, 24 h) cells were dephosphorylated with alkaline phosphatase as indicated (alk.
phosp.) and subjected to immunoblot analysis using the same antibodies as in (A). After treatment with alkaline phosphatase dephosphorylated tau displays a lower apparent mo-
lecular weight. (C) OLN-t40 cells were either left untreated (a–c) or treated with 9 μM PR-619 (d–f) for 24 h and indirect immunoﬂuorescence was carried out with antibodies
against total tau (tau 17024; a, d, red) and the phosphorylation-dependent antibody tau-1 (b, e, green). c, f, overlay with DAPI staining (blue). Scale bar: 20 μm.
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ing to the MTs and also led to the association of p62 and ubiquitinated
proteins with the cytoskeletal fraction. A similar even more pro-
nounced effect was observed after the treatment with MG-132
(Fig. 8A), which also leads to aggresome formation in OLN-t40
cells [4].
To analyze whether PR-619 alters the solubility of proteins found
in the aggregates, cell lysates were prepared and the total homoge-
nate (TH) was separated into a soluble (SN) and insoluble fraction
(P) (see Materials and methods). Immunoblot analysis revealed that
after treatment with PR-619 the amount of insoluble material was
more prominent. Tau and also tubulin were more abundant in the in-
soluble fraction (Fig. 8B). Also, a large proportion of αB-crystallin, p62
and ubiquitinated proteins remained insoluble. A similar effect was
observed after proteasomal inhibition induced by MG-132, however,
α-tubulin under this condition was highly soluble (Fig. 8B). Hence,
PR-619 led to the accumulation of p62, αB-crystallin and ubiquiti-
nated proteins, which were found in association with the MTs and
detected in the protein aggregates, and could only be solubilized in
buffers supplemented with SDS.
4. Discussion
The presence of ubiquitin in cytoplasmic protein deposits in nerve
cells and glia is a characteristic hallmark of neurodegenerativediseases [27]. Ubiquitination of proteins plays a key role in signal
transduction pathways and mediates protein stability. It represents
a reversible posttranslational modiﬁcation balanced by the actions
of E3-ligases and DUBs [7,11,12]. DUBs display a variety of proteolytic
functions, as deubiquitinating enzymes they remove ubiquitin chains
from posttranslationally modiﬁed proteins, are involved in recycling
of ubiquitin and providing a reservoir of monoubiquitin. They also
edit polyubiquitin chains, assist in targeting substrates to speciﬁc
pathways and can rescue proteins from proteasomal degradation.
Only little is known about DUB functions in the nervous system, and
particularly glial cells have not been studied. Our data, using the
broad-range isopeptidase inhibitor PR-619 [19,20], demonstrate that
DUBs are critically involved in balancing protein degradation path-
ways and maintaining cellular architecture. PR-619 previously was
shown to exert a broad DUB-inhibitory proﬁle in living cells. Incuba-
tion of HEK 293T cells resulted in an accumulation of polyubiquiti-
nated proteins and 26S proteasome complexes without blocking the
proteolytic activity of the proteasome [20].
DUB inhibition in our cellular system caused the time- and
concentration-dependent induction of HSPs, namely HSP70 and αB-
crystallin, and the accumulation of ubiquitinated proteins. Simulta-
neously, ubiquitin-positive protein aggregates, colocalizing with
HSP70 and αB-crystallin were formed. Both HSPs are part of the pro-
tein quality control system and provide a ﬁrst line of defense against
misfolded proteins. When cells are overloaded with nonnative
Fig. 8. Treatment with PR-619 promotes the association of p62, ubiquitinated proteins and tau with microtubules and alters their solubility. (A) Microtubule binding assay: OLN-t40
cells were either left untreated (Co) or treated with PR-619 (24 h; 9 μM) or with MG-132 (24 h; 1 μM). Cell lysates were separated into cytoskeletal (P) and soluble fractions (SN)
after MT assembly and were subjected to immunoblot analysis by using antibodies against α-tubulin, tau-1, tau 17024, p62, and ubiquitin (VU-1). (B) Solubility assay: cells were
treated with PR-619 (9 μM) or MG-132 (1 μM) for 24 h. Cell lysates were separated into a soluble (SN) and an insoluble (P) fraction. TH, total homogenate. Co, untreated control.
Cell lysates were subjected to immunoblot procedure by using antibodies against the individual proteins indicated on the right.
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ciate with or surround inclusion bodies. Upregulation of the small
HSPs, such as αB-crystallin, seems to be speciﬁc for glial cells, and
small HSPs are prominent constituents of glial cell inclusion bodies
in neurological disorders [28]. Hence, DUB inhibition not only leads
to an accumulation of ubiquitinated proteins but also elicits a stress
response, which is similarly observed when cells are treated with
proteasomal inhibitors. However, unlike the proteasomal inhibitor
MG-132, PR-619 does not directly inhibit proteasomal activity. Our
data indicate that the proteasomal activity is only impaired after
chronic treatment, when the cell is overloaded with denatured sub-
strates leading to an exhaustion of the UPS.
Interestingly also p62 accumulates and is recruited to the aggre-
gates and associated with the cytoskeleton after treatment with PR-
619. P62 is being considered as a cargo receptor or adaptor for the
degradation of ubiquitinated substrates by autophagy [29]. P62
binds to ubiquitinated proteins and is required for delivery of ubiqui-
tinated proteins into the forming autophagosome [8,29,30]. It binds
directly to the autophagic effector proteins LC3, and binds both
mono- and polyubiquitinated proteins with a preference to K63-
linked ubiquitin chains [29]. P62 itself is selectively degraded by
autophagy and inactivation of autophagy causes its accumulation
[30]. It then can oligomerize and aggregate, thereby enhancing the
protein aggregation process and compromising the degradation of
substrates through the UPS [31]. In neuronal cells during apoptosis
and proteasomal inhibition, its expression was reported to be induced
[32]. Taken together, p62 accumulation in neuronal and glial inclu-
sions seems to be regulated in response to elevated levels of ubiquiti-
nated proteins, which occurs also when DUBs are inhibited. Whether
PR-619 activates autophagic function as a compensatory mechanism
is currently under investigation in our laboratory.
The present data demonstrate that aggresome-like structures as-
semble around the MTOC in a time-dependent manner. While ubi-
quitin, p62, HSP70 and αB-crystallin are major constituents ofcompact and loosely packed aggregates, small tau deposits are
formed in PR-619 treated cells near the MTOC and in the cell
body, not colocalizing with ubiquitin-immunoreactivity, as opposed
to the effects of MG-132 [4]. Aggresome formation is a dynamic pro-
cess, small aggregates are formed and transported to the nascent in-
clusion body along the microtubules [33]. We have previously
demonstrated that the dynamic instability of microtubules is re-
quired for aggresome formation in oligodendroglial cells after pro-
teasomal stress [4]. After treatment with nocodazole or Taxol, the
formation of compact aggresomes around the MTOC was impaired
in OLN-t40 cells [4]. DUB inhibition in OLN-t40 cells led to MT stabi-
lization similarly as observed after treatment with Taxol. This effect
was only prominent in cells expressing the MAP tau, which indi-
cates the involvement of tau during this process. However, since
we could not detect a signiﬁcant amount of ubiquitinated tau in
the cell homogenates, we investigated the effects of PR-619 on tau
phosphorylation. Phosphorylation and dephosphorylation of tau
regulates its MT binding and stabilization capacity and its propensi-
ty of aggregate formation [34]. Our data demonstrate that PR-619
caused the dephosphorylation at the PHF-1 epitope, which in-
creased its MT-binding activity, and also an increase in tau phos-
phorylation at the 12E8 epitope was observed. The 12E8 epitope
has been connected to a reduction in tau afﬁnity to the MTs, but
also might protect tau against aggregation and proteolytic degrada-
tion [35,36]. Hence this effect on tau phosphorylation might contrib-
ute to the observed stabilization and increased bundling of the MTs.
Tau dephosphorylation in oligodendroglial cells after stress was
demonstrated to be regulated by PP2A-like phosphatase [37]. PP2A
is a serine/threonine phosphatase which is regulated by several dif-
ferent posttranslational modiﬁcations, i.e. phosphorylation, carboxy-
methylation and ubiquitination [38,39]. Polyubiquitination of PP2A
has been connected to its degradation by the proteasome, hence it
might be possible that PP2A activity is altered through DUB
inhibition.
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ment with MG-132, mainly appeared rather loosely packed. This
might be the result of MT-stabilization and its impact on transport
processes along the MTs, which are required for aggresome forma-
tion. As mentioned above, this may occur in a similar way as has
been described after the treatment with Taxol [4]. Whether other
molecules, such as HDAC6, which senses ubiquitinated proteins and
is a critical player in protein aggregate formation [40], are involved,
remains to be established. PR-619 could act through the modulation
of tau phosphorylation, or possibly also directly inﬂuence MT stability
through DUB inhibition. In this respect, the ubiquitin editing enzyme
UCH L1 is of special interest. UCH L1 is abundantly expressed in the
brain and mutations in the gene have been associated with AD and
PD [41]. It interacts with tubulin and besides being a DUB, has an ubi-
quitin ligase activity in vitro [42] and stabilizes monoubiquitin in
neurons [43]. Moreover, overexpression of UCH L1 has an inhibitory
effect on tubulin polymerization, and the presence of ubiquitin during
in vitro polymerization inhibited MT formation [44]. It might be spec-
ulated that the MT stabilizing effects of PR-619 are causally related to
its inhibitory effect on UCH L1. However, it is not clear whether α- or
β−tubulin are direct targets for ubiquitination. So far we were not
able to immunoprecipitate ubiquitinated tubulin species from PR-
619 treated cells, whichmight be due to the fact that only a small por-
tion of tubulin is modiﬁed or that during the process of precipitation
the ubiquitin moieties are removed.
To summarize, our data demonstrate that DUB inhibitors provide a
useful tool to elucidate the manifold mechanisms of DUB functions
and their dysregulation in neurodegenerative diseases. In oligoden-
droglial cells the inhibition of DUB activity by PR-619 caused cellular
stress responses, led to an overload of ubiquitinated protein species in
the cytoplasm and to the formation of protein deposits resembling
pathological inclusions observed in aggregopathies. Furthermore,
MT organization and integrity was affected, which is particularly im-
portant for the maintenance of the cellular architecture and intracel-
lular transport processes, being essential for the functionality and
survival of neural cells.
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